ANTISYNTHETASE SYNDROME
Clinical trials for ANTISYNTHETASE SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ANTISYNTHETASE SYNDROME trials appear
Sign up with your email to follow new studies for ANTISYNTHETASE SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for Long-Term myositis control
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases called myositis. People who already took part in a previous study of this drug can join. They will receive the drug for up to 51 months and then be followed for 56 da…
Matched conditions: ANTISYNTHETASE SYNDROME
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Early IVIg boost may tame muscle disease before it disables
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis leads to faster improvement than steroids alone. Myositis is a group of rare diseases that cause muscle inflammation and weakness. The trial includes 44 adults diagno…
Matched conditions: ANTISYNTHETASE SYNDROME
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated May 19, 2026 12:01 UTC